Is Repligen profitable and growing in 2026?

Repligen reported FY2025 revenue of $738 million, up 16% reported and 14% organic year over year, as of December 31, 2025. FY2026 guidance issued February 24, 2026 calls for $810 to $840 million revenue, 10 to 14% reported growth, indicating continued expansion.

Who is Repligen's biggest competitor?

Danaher Corporation, via its Cytiva and Pall businesses, is Repligen's largest rival, historically holding an estimated 80 to 90% share of the Protein A resin market. Sartorius AG and Thermo Fisher Scientific also compete directly in bioprocessing filtration and chromatography.

Could AI replace Repligen's products?

Unlikely for its core business. Repligen's value is physical, GMP-regulated hardware and consumables embedded in validated drug filings, which AI software cannot replace. Only a thin process-analytics layer, like its PATsmart tools from the March 2025 908 Devices acquisition, is AI-exposed.

Is Repligen a safe company to join in 2026?

Headcount grew to 2,000 by December 31, 2025, up 12.5% from 1,778 in 2024, after a 2023 to 2024 dip from 2,025 in 2022. The pending $1.5 billion BioLife Solutions acquisition, announced July 22, 2026, signals expansion, though integration risk exists.

Is Repligen being acquired or is it the acquirer?

Repligen is the acquirer. On July 22, 2026 it announced a definitive agreement to buy BioLife Solutions for about $1.5 billion enterprise value at $31.00 per share, expected to close in Q4 2026, expanding into cell therapy tools.

Why did Repligen's stock or revenue face risk from Sarepta in 2025?

Sarepta's Elevidys gene therapy program contributed $10 million in the first half of 2025 plus $3 million in July, but Repligen guided to minimal future revenue from it, a roughly 1% growth headwind, after an FDA clinical hold in July 2025 that was lifted July 28, 2025.

Biotech tools companies · United States

Repligen Corporation

repligen.com ↗

Makes Protein A resins, filtration and other hardware/consumables used to manufacture biologic drugs.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: BioLife Solutions acquisition expected to close pending shareholder vote and regulatory clearance

The call

Repligen keeps growing double digits by holding onto drugs already validated with its equipment, while giants compete hard but mostly at the edges.

Repligen sells machines and consumables (like filters and resins) that drug companies use to manufacture biologics, which are medicines made from living cells. Once a drug company puts Repligen equipment into their FDA-approved recipe, switching to a rival like Danaher or Sartorius would require years of testing and millions of dollars to re-prove the drug works the same way, so customers stick with Repligen for decades. The real question is whether Repligen keeps winning new drug programs or just profits from old ones, which you can track by watching if their customer orders keep outpacing their sales each quarter.

Why

AI pressure: None apparent. AI-driven drug discovery is speeding up biologics pipelines, which feeds demand for Repligen's tools rather than threatening them. Could AI do the core job? Unlikely.

Bigger players: Danaher Corporation (Cytiva/Pall). Danaher, Sartorius and Thermo Fisher sell competing Protein A resins and filtration systems but have not displaced Repligen's installed base in a decade. Could a giant copy it? Probably.

What protects it. Once a customer's drug filing (BLA/MAA) is approved with Repligen hardware inside, swapping suppliers means multi-year, multi-million-dollar revalidation.

What would change this call

Design-in wins/losses on new drug programs vs Danaher/Cytiva and Sartorius over next year. Shows whether Repligen's moat extends to new programs or only defends installed base.
Whether orders continue exceeding non-COVID revenue past Q2 2025's 8-quarter streak. A break would signal demand or competitive displacement.
Completion and integration outcome of BioLife Solutions acquisition by Q4 2026. Shows execution risk that could weaken balance sheet or distract from core moat defense.

Key numbers

FY2025 revenue $738M, up 16% reported (2025-12-31)
Q4 2025 revenue $198M, up 18% reported (2025-12-31)
8 straight quarters of orders exceeding revenue (2025-06-30)

Named risks

BioLife Solutions acquisition could be delayed, renegotiated, or blocked by shareholder or regulatory review before Q4 2026 close. Severity: medium
Customer concentration in gene therapy revenue tied to Sarepta's Elevidys, subject to FDA regulatory action as seen in July 2025 clinical hold. Severity: medium
Design in share loss to Danaher or Sartorius on new drug programs could erode future growth beyond the installed base. Severity: medium
Integration risk from the roughly $1.5 billion BioLife deal impairing balance sheet or diverting management focus. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Danaher Corporation (Cytiva/Pall)	contesting	Holds an estimated 80 to 90% historical share of Protein A resin, per industry reports, undated
Sartorius AG	contesting	Named alongside Danaher and Thermo Fisher as leading bioprocessing player in industry reports, 2026-01-02
Thermo Fisher Scientific	contesting	Competes directly in bioprocess filtration and analytics markets, per market research dated 2026-01-02
Merck KGaA	gaining on	Announced $11.3 billion Bio-Techne acquisition around 2026-06-22, escalating tools sector consolidation

Questions people ask

Is Repligen profitable and growing in 2026?: Repligen reported FY2025 revenue of $738 million, up 16% reported and 14% organic year over year, as of December 31, 2025. FY2026 guidance issued February 24, 2026 calls for $810 to $840 million revenue, 10 to 14% reported growth, indicating continued expansion.
Who is Repligen's biggest competitor?: Danaher Corporation, via its Cytiva and Pall businesses, is Repligen's largest rival, historically holding an estimated 80 to 90% share of the Protein A resin market. Sartorius AG and Thermo Fisher Scientific also compete directly in bioprocessing filtration and chromatography.
Could AI replace Repligen's products?: Unlikely for its core business. Repligen's value is physical, GMP-regulated hardware and consumables embedded in validated drug filings, which AI software cannot replace. Only a thin process-analytics layer, like its PATsmart tools from the March 2025 908 Devices acquisition, is AI-exposed.
Is Repligen a safe company to join in 2026?: Headcount grew to 2,000 by December 31, 2025, up 12.5% from 1,778 in 2024, after a 2023 to 2024 dip from 2,025 in 2022. The pending $1.5 billion BioLife Solutions acquisition, announced July 22, 2026, signals expansion, though integration risk exists.
Is Repligen being acquired or is it the acquirer?: Repligen is the acquirer. On July 22, 2026 it announced a definitive agreement to buy BioLife Solutions for about $1.5 billion enterprise value at $31.00 per share, expected to close in Q4 2026, expanding into cell therapy tools.
Why did Repligen's stock or revenue face risk from Sarepta in 2025?: Sarepta's Elevidys gene therapy program contributed $10 million in the first half of 2025 plus $3 million in July, but Repligen guided to minimal future revenue from it, a roughly 1% growth headwind, after an FDA clinical hold in July 2025 that was lifted July 28, 2025.

Timeline

2026-07-22Announced definitive agreement to acquire BioLife Solutions for about $1.5 billion
2026-07-21Q1 2026 revenue reported at $194.25 million, up 14.8% year over year
2026-02-24FY2025 results: $738 million revenue, issued FY2026 guidance of $810 to $840 million
2025-07-29Q2 2025 revenue $182 million, eighth straight quarter of orders exceeding revenue
2025-07-28FDA lifted clinical hold on Sarepta's Elevidys gene therapy
2025-03-04Closed acquisition of 908 Devices bioprocessing analytics portfolio for about $70.3 million
2023-12-31Headcount fell to 1,783 from 2,025 in 2022 amid post-COVID demand correction
1981Repligen founded by Alexander Rich and Paul Schimmel

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE